Now Reading: Aurobindo Pharma Q1 profit rises 25% to Rs 1,032 crore
-
01
Aurobindo Pharma Q1 profit rises 25% to Rs 1,032 crore
Aurobindo Pharma’s consolidated net profit rose 25.2% year on year to Rs 1,032 crore in the June quarter of FY27, The Hindu reports. Revenue from operations increased 16.3% to Rs 9,150 crore,…
The Story in Brief
Aurobindo Pharma’s consolidated net profit rose 25.2% year on year to Rs 1,032 crore in the June quarter of FY27, The Hindu reports. Revenue from operations increased 16.3% to Rs 9,150 crore, with growth across its businesses. Formulations revenue rose 16.5% to Rs 8,101 crore. US formulations revenue grew 8.1% to Rs 3,770 crore, while Europe revenue climbed 25.6% to Rs 2,937 crore. API revenue increased 14.6% to Rs 1,049 crore.
The company attributed US growth mainly to higher volumes and new launches, partly offset by the absence of transient product sales. Its board also approved the merger of Eugia Steriles and Eugia SEZ with Eugia Pharma Specialities. Aurobindo said the consolidation will cut administrative overheads and improve treasury management. All three units make injectable pharmaceutical products.
The Indian Opinion
The easy story is that a 25% profit jump proves every part of Aurobindo’s business is firing equally. The numbers are more mixed. US growth was modest compared with Europe, and the company itself cited volume gains and new launches rather than a broad pricing surge. The merger may reduce duplication, but its value will depend on actual savings and execution. The next quarter’s revenue and margin figures should show whether this is durable growth or a one-quarter lift.
Source: thehindu.com
This story was synthesised by AI from the source linked above.
